Hayadan > Science in Israel > Biotechnology in Israel > biotechnology companies > Byline

Byline

Biotechnology Cluster: Pluristem received the approval of the US Registrar for a key patent of the company

The science service
September 20, 2013
No comments

Bioline R.X has completed the recruitment of patients for phase 2b of the clinical trials for a new drug for the treatment of schizophrenia

The science service
May 3, 2009
No comments

Beauline R. X advances a step in approving a drug to treat heart attacks

The science service
January 12, 2009
2 תגובות

Can seaweed mend a broken heart?

Scientific American Israel
September 3, 2008
3 תגובות

Synthetic molecules developed by researchers from the Hebrew University may lead to a new generation of anti-cancer drugs

The Hebrew University
June 1, 2008
No comments

Bioline R.X. Announces Initiation of Phase II Human Clinical Trials of BL-1020, a New Drug for the Treatment of Schizophrenia

The science service
July 28, 2007
No comments

Bioline R.X. Launches a program for advanced development

The science service
June 6, 2007
No comments

Bioline R.X. Begins clinical trials to test the effectiveness of BL-1020, an antipsychotic drug for the treatment of schizophrenia

Avi Blizovsky
May 19, 2007
4 תגובות

Beauline R. Ex. Signed a licensing agreement with the Hebrew University and Tel Aviv University for a potential drug to treat inflammatory diseases

Avi Blizovsky
March 23, 2007
5 תגובות

Licensing agreement for Bioline R. Ex. With Bo Gurion University and with the general medicine for anti-inflammatories

The science service
September 18, 2006
No comments

The technological incubators committee approved the establishment of a biotechnological incubator in Jerusalem

Avi Blizovsky
December 2, 2004
No comments